FR04C0020I2 - ACYLATED INSULIN - Google Patents

ACYLATED INSULIN

Info

Publication number
FR04C0020I2
FR04C0020I2 FR04C0020C FR04C0020C FR04C0020I2 FR 04C0020 I2 FR04C0020 I2 FR 04C0020I2 FR 04C0020 C FR04C0020 C FR 04C0020C FR 04C0020 C FR04C0020 C FR 04C0020C FR 04C0020 I2 FR04C0020 I2 FR 04C0020I2
Authority
FR
France
Prior art keywords
acylated insulin
acylated
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR04C0020C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR04C0020(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/en
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of FR04C0020I1 publication Critical patent/FR04C0020I1/fr
Application granted granted Critical
Publication of FR04C0020I2 publication Critical patent/FR04C0020I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FR04C0020C 1993-09-17 2004-09-06 ACYLATED INSULIN Active FR04C0020I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK104493A DK104493D0 (en) 1993-09-17 1993-09-17 HIS UNKNOWN PEPTIDES
US19082994A 1994-02-02 1994-02-02
PCT/DK1994/000347 WO1995007931A1 (en) 1993-09-17 1994-09-16 Acylated insulin

Publications (2)

Publication Number Publication Date
FR04C0020I1 FR04C0020I1 (en) 2004-10-29
FR04C0020I2 true FR04C0020I2 (en) 2005-05-27

Family

ID=26065125

Family Applications (1)

Application Number Title Priority Date Filing Date
FR04C0020C Active FR04C0020I2 (en) 1993-09-17 2004-09-06 ACYLATED INSULIN

Country Status (30)

Country Link
US (1) US5750497A (en)
EP (2) EP0792290B1 (en)
JP (3) JP3014764B2 (en)
KR (1) KR100310122B1 (en)
CN (1) CN1056618C (en)
AT (1) ATE204882T1 (en)
AU (2) AU682061B2 (en)
BG (1) BG61611B1 (en)
BR (1) BR9407508A (en)
CA (1) CA2171424C (en)
CZ (1) CZ287945B6 (en)
DE (2) DE69428134T2 (en)
DK (1) DK0792290T3 (en)
ES (1) ES2163451T3 (en)
FI (1) FI117055B (en)
FR (1) FR04C0020I2 (en)
HU (1) HU217684B (en)
IL (1) IL110977A (en)
LU (1) LU91101I2 (en)
NL (1) NL300160I2 (en)
NO (3) NO316944B1 (en)
NZ (1) NZ273285A (en)
PL (1) PL178466B1 (en)
PT (1) PT792290E (en)
RO (1) RO112873B1 (en)
RU (1) RU2164520C2 (en)
SI (1) SI0792290T1 (en)
SK (1) SK282495B6 (en)
UA (1) UA45321C2 (en)
WO (1) WO1995007931A1 (en)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
DE4437604A1 (en) * 1994-10-21 1996-04-25 Basf Ag Conjugates of a poly or oligopeptide and a low molecular weight lipophilic compound
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
WO1996029344A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
ES2167751T5 (en) * 1996-06-20 2012-03-30 Novo Nordisk A/S Insulin preparations containing a halide
DE69731105T2 (en) * 1996-07-11 2005-11-17 Novo Nordisk A/S METHOD FOR SELECTIVE ACETYLATION
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
CN1259142A (en) * 1997-03-20 2000-07-05 诺沃挪第克公司 Zinc free insulin crystals for use in pulmonary compositions
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EP0911035A3 (en) * 1997-10-24 2002-08-21 Eli Lilly And Company Insoluble insulin compositions
CA2306877A1 (en) * 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (en) 1997-12-23 2000-11-07 Lilly Co Eli INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
JP2002500196A (en) * 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ Stabilized insulin composition
JP2002504527A (en) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ GLP-2 derivatives with more than 25% helical component forming partially organized micellar-like aggregates
DE19825447A1 (en) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh New insulin analogues with increased zinc formation
JP2002518408A (en) * 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン Insulin analogues
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
DK1265630T3 (en) 2000-03-24 2006-10-09 Genentech Inc Use of insulin for the treatment of cartilage disease
EP1292324A2 (en) * 2000-05-05 2003-03-19 Novo Nordisk A/S Critical illness neuropathy
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
AU2001269307A1 (en) * 2000-07-10 2002-01-21 Btg International Limited Insulin derivatives and synthesis thereof
KR20030005204A (en) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 Sympathetic-activating perfume composition
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE60214361T2 (en) * 2001-05-02 2007-09-13 Novo Nordisk A/S PROCESS FOR THE PRODUCTION OF GALLEN ACID
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
PT1430082E (en) 2001-09-07 2010-01-15 Biocon Ltd Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
CA2463803A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
ES2344448T3 (en) 2001-11-19 2010-08-27 Novo Nordisk A/S PROCESS TO PREPARE INSULIN COMPOUNDS.
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
ES2360182T3 (en) * 2002-05-07 2011-06-01 Novo Nordisk A/S SOLUBLE FORMULATIONS THAT INCLUDE MONOMERIC INSULIN AND ACILATED INSULIN.
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
CA2500123A1 (en) * 2002-09-25 2004-04-08 Novo Nordisk A/S Method for producing acylated peptides
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
EP1641616B1 (en) 2003-06-27 2011-04-13 Novo Nordisk A/S High moisture barrier container for medical liquid compositions
PL2107069T3 (en) * 2003-08-05 2013-06-28 Novo Nordisk As Novel insulin derivatives
ES2472421T3 (en) 2003-08-05 2014-07-01 Novo Nordisk A/S New insulin derivatives
JP2007532096A (en) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ Method for producing acylated insulin
EP1687019B1 (en) 2003-11-20 2017-11-22 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
JP5697831B2 (en) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス Single chain insulin
CN1898087A (en) 2003-12-22 2007-01-17 诺沃挪第克公司 Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids
BRPI0506864A (en) 2004-01-21 2007-05-29 Novo Nordisk As method for conjugating peptides, conjugated peptide, compound and pharmaceutically acceptable salts, prodrugs and solvates thereof, pharmaceutical composition, use of a compound, and method for treating disease
CA2558835C (en) * 2004-03-12 2011-06-28 Biodel, Inc. Rapid acting drug delivery compositions
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP2292653B1 (en) 2005-02-02 2014-05-21 Novo Nordisk A/S Novel insulin derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
CN101180081B (en) 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 Stable polypeptide formulations
EP1888117A1 (en) * 2005-05-25 2008-02-20 Novo Nordisk A/S Stabilized polypeptide formulations
WO2006125765A2 (en) * 2005-05-26 2006-11-30 Novo Nordisk A/S Acylated insulin with high purity
AU2006264966B2 (en) 2005-07-04 2013-02-21 High Point Pharmaceuticals, Llc Histamine H3 receptor antagonists
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2006342449B2 (en) 2005-11-17 2012-03-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
JP4808785B2 (en) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス Insulin composition and method for producing the composition
SI1984009T1 (en) * 2006-01-18 2013-02-28 Qps, Llc Pharmaceutical compositions with enhanced stability
ES2387955T3 (en) 2006-02-27 2012-10-04 Novo Nordisk A/S Insulin derivatives
JP2009530242A (en) * 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス Acylated single chain insulin
ES2397659T3 (en) 2006-03-15 2013-03-08 Novo Nordisk A/S Mixtures of amylin and insulin
KR101280333B1 (en) 2006-03-28 2013-07-02 하이 포인트 파마슈티칼스, 엘엘씨 Benzothiazoles having histamine ｈ３ receptor activity
JP5118692B2 (en) 2006-04-24 2013-01-16 イーライ リリー アンド カンパニー Cyclohexyl substituted pyrrolidinones as inhibitors of 11-β-hydroxysteroid dehydrogenase 1
CN101437849B (en) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 Insulin derivates
ES2548393T3 (en) 2006-05-09 2015-10-16 Novo Nordisk A/S Insulin derivative
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
SI2079732T1 (en) 2006-05-29 2012-03-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
MX2009000434A (en) 2006-07-11 2009-01-29 Qps Llc Pharmaceutical compositions for sustained release delivery of peptides.
CN101573133B (en) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 PEGylated, extended insulins
KR101729986B1 (en) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 Protease resistant insulin analogues
JP5503968B2 (en) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス Method for producing mature insulin polypeptide
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP2164458A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
MX2010003979A (en) * 2007-10-16 2010-06-02 Biocon Ltd An orally administerable solid pharmaceutical composition and a process thereof.
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
ES2543393T3 (en) * 2007-11-08 2015-08-18 Novo Nordisk A/S Insulin derivative
US8937042B2 (en) 2007-11-16 2015-01-20 Novo Nordisk A/S Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
MX2010007342A (en) * 2008-01-04 2010-08-26 Biodel Inc Insulin formulations for insulin release as a function of tissue glucose levels.
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
TWI451876B (en) 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
US9090705B2 (en) 2008-08-07 2015-07-28 Biocon Limited Process for preparation of insulin compounds
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP2012509879A (en) 2008-11-21 2012-04-26 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー Adamantylbenzamide compounds
JP2012516340A (en) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド Synthetic conjugates and uses thereof
EA027757B1 (en) * 2009-01-28 2017-08-31 Смартселлз, Инк. Conjugate for controlled insulin delivery
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc Terminally-functionalized conjugates and uses thereof
WO2010140148A1 (en) 2009-06-01 2010-12-09 Yeda Research And Development Co . Ltd Prodrugs containing albumin binding probe
BR112012012945A2 (en) 2009-11-25 2020-12-29 Arisgen Sa MUCOSAL RELEASE COMPOSITION, ITS PRODUCTION METHOD, PRE-FORMED PEPTIDE COMPLEX, KIT AND USE OF AN ACTIVE PEPTIDE AGENT
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (en) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
TW201141513A (en) 2010-04-14 2011-12-01 Sanofi Aventis Insulin-siRNA conjugates
KR20130092972A (en) * 2010-05-10 2013-08-21 노보 노르디스크 에이/에스 Process for the preparation of insulin-zinc complexes
US20140315797A1 (en) * 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
RU2013123515A (en) 2010-10-27 2014-12-10 Ново Нордиск А/С DIABETES TREATMENT USING INSULIN INJECTIONS INJECTED WITH VARIOUS INTERVALS
CA2822591C (en) 2010-12-22 2020-12-29 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
CN102504022A (en) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 Proinsulin containing protecting lysine and preparation method for insulin by utilizing proinsulin
AU2012350586B2 (en) * 2011-12-15 2017-02-02 Jiangsu Hengrui Medicine Co., Ltd. Human insulin analogue and acylated derivative thereof
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
MX363119B (en) 2012-05-01 2019-03-11 Novo Nordisk As Pharmaceutical composition.
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
KR102302634B1 (en) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 Modified therapeutic agents and compositions thereof
MX366636B (en) * 2013-10-07 2019-07-17 Novo Nordisk As Novel derivative of an insulin analogue.
KR102455171B1 (en) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2996455A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
TWI747929B (en) * 2016-08-02 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 An acylation derivative of human insulin or analog thereof
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
EP4129321A1 (en) 2016-12-05 2023-02-08 Nuritas Limited Compositions comprising peptide wkdeagkplvk
RU2758367C2 (en) 2016-12-16 2021-10-28 Ново Нордиск А/С Pharmaceutical compositions containing insulin
KR20200044016A (en) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 GLP-1 composition and use
US20200283492A1 (en) * 2017-09-29 2020-09-10 Hanmi Pharm Co., Ltd. Long acting protein complex having an enhanced efficiency
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
WO2019154311A1 (en) 2018-02-09 2019-08-15 江苏恒瑞医药股份有限公司 Codon optimized precursor gene and signal peptide gene of human insulin analogue
CN111601819A (en) 2018-05-24 2020-08-28 江苏恒瑞医药股份有限公司 Preparation method of precursor of recombinant human insulin or analogue thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20200017078A (en) 2018-08-08 2020-02-18 주식회사 대웅제약 Long-acting Insulin Analog and Derivatives Thereof
AU2019398579A1 (en) 2018-12-11 2021-07-29 Sanofi Peptide binder
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
CN111909255A (en) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 Insulin derivatives and process for preparing the same
TW202120536A (en) 2019-07-31 2021-06-01 美商美國禮來大藥廠 Relaxin analogs and methods of using the same
MX2022006251A (en) 2019-12-11 2022-06-22 Novo Nordisk As Novel insulin analogues and uses thereof.
KR20220121833A (en) 2019-12-30 2022-09-01 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 insulin derivatives
BR112022013042A2 (en) 2019-12-30 2022-10-18 Gan & Lee Pharmaceuticals Co Ltd FORMULA B COMPOUND, PHARMACEUTICAL FORMULATION, PHARMACEUTICAL COMPOSITION, METHOD TO TREAT OR PREVENT HYPERGLYCEMIA, DIABETES AND/OR OBESITY
BR112022013795A2 (en) 2020-02-18 2022-09-13 Novo Nordisk As LIQUID PHARMACEUTICAL COMPOSITION AND KIT
BR112022019687A2 (en) 2020-03-31 2022-12-20 Protomer Tech Inc CONJUGATES FOR SELECTIVE RESPONSIBILITY TO VICINAL DIOLS
WO2022109078A1 (en) 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024051787A1 (en) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 Long-acting acylated insulin derivative and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) * 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (en) * 1980-07-24 1982-01-25 Forenede Bryggerier As PROCEDURE FOR ENZYMATIC REPLACEMENT OF B-30 AMINO ACID IN INSULINES
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (en) * 1988-04-05 1989-10-11 Kodama Kk Insulin derivative and use thereof
AU8091091A (en) * 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Also Published As

Publication number Publication date
WO1995007931A1 (en) 1995-03-23
NZ273285A (en) 1997-10-24
FI961220A0 (en) 1996-03-15
RO112873B1 (en) 1998-01-30
PT792290E (en) 2002-01-30
JP3014764B2 (en) 2000-02-28
US5750497A (en) 1998-05-12
EP0792290B1 (en) 2001-08-29
BG100420A (en) 1996-12-31
SK32496A3 (en) 1996-11-06
CA2171424A1 (en) 1995-03-23
DE122004000035I1 (en) 2005-02-24
DE122004000035I2 (en) 2009-08-06
EP1132404A3 (en) 2002-03-27
NO961070L (en) 1996-05-15
HU217684B (en) 2000-03-28
FI117055B (en) 2006-05-31
FI961220A (en) 1996-05-14
NO2004006I1 (en) 2004-10-11
CZ78996A3 (en) 1996-10-16
CZ287945B6 (en) 2001-03-14
NO2004006I2 (en) 2008-02-04
EP1132404A2 (en) 2001-09-12
CN1056618C (en) 2000-09-20
DE69428134T2 (en) 2002-05-02
JPH09502867A (en) 1997-03-25
KR100310122B1 (en) 2002-04-24
AU682061B2 (en) 1997-09-18
FR04C0020I1 (en) 2004-10-29
SI0792290T1 (en) 2001-12-31
ES2163451T3 (en) 2002-02-01
CN1133598A (en) 1996-10-16
UA45321C2 (en) 2002-04-15
NL300160I2 (en) 2005-07-01
JP4060583B2 (en) 2008-03-12
CA2171424C (en) 2002-06-04
NO2017041I2 (en) 2018-11-19
IL110977A (en) 2000-06-29
EP0792290A1 (en) 1997-09-03
HU9600676D0 (en) 1996-05-28
ATE204882T1 (en) 2001-09-15
JP2002308899A (en) 2002-10-23
AU4846197A (en) 1998-02-19
LU91101I2 (en) 2004-11-08
HUT75991A (en) 1997-05-28
JP3917333B2 (en) 2007-05-23
PL313444A1 (en) 1996-07-08
PL178466B1 (en) 2000-05-31
SK282495B6 (en) 2002-02-05
JP2000060556A (en) 2000-02-29
KR960704925A (en) 1996-10-09
DK0792290T3 (en) 2001-10-01
NO2017041I1 (en) 2017-08-01
AU7652094A (en) 1995-04-03
NL300160I1 (en) 2004-12-01
NO316944B1 (en) 2004-07-05
NO961070D0 (en) 1996-03-15
BG61611B1 (en) 1998-01-30
BR9407508A (en) 1997-01-07
IL110977A0 (en) 1994-11-28
RU2164520C2 (en) 2001-03-27
DE69428134D1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
FR04C0020I2 (en) ACYLATED INSULIN
ATE237635T1 (en) ACYLATED INSULIN ANALOGUES
DE69434952D1 (en) MUCH-CHIP MODULE
NO302553B1 (en) Gardinforbindelses assembly
DE69404533T3 (en) inkjet
DE69421839D1 (en) Antidiabetic
DE69401251D1 (en) CRYSTAT ASSEMBLY
DE59407205D1 (en) Structure
FI930640A (en) Rack
DE9303795U1 (en) Spacers
DE9314742U1 (en) Immersion-proof housing
KR940019909U (en) fishbowl
DE9301963U1 (en) Structure
KR940020168U (en) overpriced
DE69419190D1 (en) Printhead
DE9318280U1 (en) Structure
NO941620D0 (en) Betongelement assembly
KR940021931U (en) overpriced
KR940019615U (en) Arrow structure
KR950015090U (en) Arrow structure
DE9317397U1 (en) Case
KR950010588U (en) fishbowl
DK125993D0 (en) CASETTE RE-RECORDER
BR7300232U (en) Electronic Ethometer
BR7300233U (en) Electronic lactometer